4 Healthcare Stock Stories for Investment Wellness

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Pharmacyclics (NASDAQ:PCYC): Current price $88.00

The firm’s shares were downgraded at Leerink Swann from Outperform to Market Perform, but the research firm increased its price target from $80 to $97 on a recent rally. The analyst said, “Following the shares’ recent rally and the realization of a number of catalysts, we are downgrading PCYC from Outperform to Market Perform. We continue to see ibrutinib as a rare asset in the biotech group with striking activity demonstrated in chronic lymphocytic leukemia and mantle cell lymphoma, but we believe the current valuation has priced in significant sales from the larger indications in diffuse large B-cell lymphoma , follicular lymphoma  and multiple myeloma.”

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

pcyc

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business